Atrasentan
- Generic Name
- Atrasentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H38N2O6
- CAS Number
- 173937-91-2
- Unique Ingredient Identifier
- V6D7VK2215
- Background
Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists. It is a novel, selective endothelin A receptor antagonist (SERA).
- Indication
Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05834738
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic, Birmingham, Alabama, United States
🇺🇸Fides Clinical Research, Atlanta, Georgia, United States
🇺🇸NANI Research, Oak Brook, Illinois, United States
Atrasentan in Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT04573478
- Locations
- 🇺🇸
Liberty Research Center, Dallas, Texas, United States
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Peking University People's Hospital, Beijing, China
Atrasentan in Patients With Proteinuric Glomerular Diseases
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04573920
- Locations
- 🇬🇧
Royal Hospital London, London, England, United Kingdom
🇦🇺Monash Health- Monash Medical Centre, Clayton, Victoria, Australia
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
Atrasentan Spermatogenesis and Testicular Function
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT02118714
- Locations
- 🇺🇸
Tulane Univ /ID# 130308, New Orleans, Louisiana, United States
🇺🇸Frank Clark Urology Center /ID# 147794, Santa Monica, California, United States
🇺🇸Southern IL Univ School of Med /ID# 129010, Springfield, Illinois, United States
Study Of Diabetic Nephropathy With Atrasentan
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 5107
- Registration Number
- NCT01858532
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 48
- Registration Number
- NCT01399580
- Locations
- 🇺🇸
Site Reference ID/Investigator# 56927, Azusa, California, United States
🇺🇸Site Reference ID/Investigator# 70173, Los Angeles, California, United States
🇺🇸Site Reference ID/Investigator# 55543, Flushing, New York, United States
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 149
- Registration Number
- NCT01356849
- Locations
- 🇺🇸
Site Reference ID/Investigator# 45998, Los Angeles, California, United States
🇺🇸Site Reference ID/Investigator# 46031, Pembroke Pines, Florida, United States
🇺🇸Site Reference ID/Investigator# 46666, Chicago, Illinois, United States
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2010-04-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 200
- Registration Number
- NCT00271492
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2010-05-10
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT00181558
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Long Term Safety Study With Atrasentan
- Conditions
- First Posted Date
- 2005-08-08
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 166
- Registration Number
- NCT00127478
- Locations
- 🇺🇸
University of Pittsburgh Department of Urology, Pittsburgh, Pennsylvania, United States
🇺🇸South Florida Medical Research, Aventura, Florida, United States
🇺🇸Prostate Oncology Specialists, Marina Del Rey, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.